1. Constine LS, Williams JP, Morris M, Rubin P, Okunieff P. Late effects of cancer treatment on normal tissues. In: Perez CA, Brady LW, Halperin EC, Schmıdt-Ullrich RK, editors. Principles and practice of radiation oncology. 4th ed. Philadelphia: Lippincott Williams and Wilkins; 2004. p. 357–90.
2. Mose S, et al. Radiation enhancement of gemcitabine in two human squamous cell carcinoma cell lines. Anticancer Res. 2000;20(A):401–5.
3. Shewach DS, Hahn TM, Chang E, Hertel LW, Lawrence TS. Metabolism of 2′2′-difluoro-2′-deoxycytidine and radiation sensitization of human colon carcinoma cells. Cancer Res. 1994;54:3218–23.
4. Milas L, et al. Enhancement of tumor radioresponse in vivo by gemcitabine. Cancer Res. 1999;59:107–14.
5. Mason KA, et al. Maximizing therapeutic gain with gemcitabine and fractionated radiation. Int J Radiat Oncol Biol Phys. 1999;44:1125–35. doi: 10.1016/S0360-3016(99)00134-0 .